Why AbbVie Stock Flopped on Friday

Core Viewpoint - AbbVie's latest earnings release did not meet investor expectations, leading to a stock price decline of over 4%, contrasting with a slight gain in the S&P 500 index [1] Financial Performance - AbbVie reported third-quarter revenue of approximately $15.78 billion, reflecting a 9% year-over-year increase, driven by strong sales of blockbuster drugs [2] - The company achieved a net income of $3.3 billion ($1.86 per share) on a non-GAAP basis, up from $2.3 billion in the same quarter of 2024, surpassing analyst estimates for both revenue and adjusted net income [3] Management Commentary - CEO Robert Michael highlighted the significant momentum in key areas of AbbVie's portfolio and emphasized progress in advancing the pipeline and investing in innovation for long-term growth [4] Guidance and Market Reaction - AbbVie raised its adjusted net income guidance for 2025 to a range of $10.61 to $10.65 per share, although this is below the consensus estimate of $10.86 [6]